scholarly journals Clinical Impact and Risk Factors of Nonsusceptibility to Third-Generation Cephalosporins Among Hospitalized Adults With Monomicrobial Enterobacteriaceae Bacteremia in Southern Taiwan: A Multicenter Study

2020 ◽  
Author(s):  
Tsao-Chin Lin ◽  
Yuan-Pin Hung ◽  
Ching-Chi Lee ◽  
Wei-Tang Lin ◽  
Li-Chen Huang ◽  
...  
Keyword(s):  
Risk Factors ◽  
Mortality Rate ◽  
Generation Cephalosporin ◽  
Rapid Identification ◽  
First Episode ◽  
Prognostic Impact ◽  
Third Generation ◽  
Crude Mortality ◽  
District Hospitals ◽  
Southern Taiwan

Abstract Background: Reducing effectiveness of broad-spectrum cephalosporins against Enterobacteriaceae infections has been recognized. This study aimed to investigate risk factors and clinical significance of third-generation cephalosporin nonsusceptibility (3GC-NS) among the cases of monomicrobial Enterobacteriaceae bacteremia (mEB) at regional or district hospitals.Methods: The study was conducted at three hospitals at southern Taiwan between Jan. 2017 and Oct. 2019. Only the first episode of mEB from each adult (aged ≥20 years) was included. The primary outcome was in-hospital crude mortality.Results: Overall there were 499 episodes of adults with mEB included, and their mean age was 74.5 years. Female predominated, accounting for 53% of all patients. Escherichia coli (62%) and Klebsiella pneumoniae (21%) were two major causative species. The overall mortality rate was 15% (73/499), and patients infected by 3GC-NS isolates (34%, 172/499) had a higher mortality rate than those by 3GC-susceptible isolates (66%, 327/499) (21% vs. 11%, P=0.005). By the multivariate analysis, 3GC-NS was the only independent prognostic determinant (adjusted odds ratio [AOR], 1.78; P=0.04). Of note, male (AOR 2.02, P=0.001), nosocomial-acquired bacteremia (AOR 2.77, P<0.001), and usage of nasogastric tube (AOR 2.01, P=0.002) were positively associated with 3GC-NS, but P. mirabilis bacteremia (AOR 0.28, P=0.01) and age (AOR 0.98, P=0.04) negatively with 3GC-NS.Conclusion: For adults with Enterobacteriaceae bacteremia, 3GC-NS signifies a significant prognostic impact. Efforts to rapid identification of such antimicrobial resistance profiles should be incorporated into antimicrobial stewardship programs to achieve favorable outcomes.

scholarly journals Impact of Cefotaxime Non-susceptibility on the Clinical Outcomes of Bacteremic Pneumococcal Pneumonia

2019 ◽  
Vol 8 (8) ◽  
pp. 1150
Author(s):  
Cillóniz ◽  
de la Calle ◽  
Dominedò ◽  
García-Vidal ◽  
Cardozo ◽  
...  
Keyword(s):  
Mortality Rate ◽  
Clinical Outcomes ◽  
Multivariate Analyses ◽  
Generation Cephalosporin ◽  
Third Generation ◽  
Factors Associated ◽  
Bacteremic Pneumonia ◽  
Bacteremic Pneumococcal Pneumonia ◽  
The Impact ◽  
Hospital Clinic

Background: We aimed to analyze the impact of cefotaxime non-susceptibility on the 30-day mortality rate in patients receiving a third-generation cephalosporin for pneumococcal bacteremic pneumonia. Methods: We conducted a retrospective observational study of prospectively collected data from the Hospital Clinic of Barcelona. All adult patients with monomicrobial bacteremic pneumonia due to Streptococcus pneumoniae and treated with a third-generation cephalosporin from January 1991 to December 2016 were included. Risk factors associated with 30-day mortality were evaluated by univariate and multivariate analyses. Results: During the study period, 721 eligible episodes were identified, and data on the susceptibility to cefotaxime was obtainable for 690 episodes. Sixty six (10%) cases were due to a cefotaxime non-susceptible strain with a 30-day mortality rate of 8%. Variables associated with 30-day mortality were age, chronic liver disease, septic shock, and the McCabe score. Infection by a cefotaxime non-susceptible S. pneumoniae did not increase the mortality rate. Conclusion: Despite the prevalence of cefotaxime, non-susceptible S. pneumoniae has increased in recent years. We found no evidence to suggest that patients hospitalized with bacteremic pneumonia due to these strains had worse clinical outcomes than patients with susceptible strains.

scholarly journals Characterization of AmpC-hyperproducing Escherichia coli from humans and dairy farms collected in parallel in the same geographical region

2020 ◽  
Vol 75 (9) ◽  
pp. 2471-2479 ◽  
Author(s):  
Maryam Alzayn ◽  
Jacqueline Findlay ◽  
Hannah Schubert ◽  
Oliver Mounsey ◽  
Virginia C Gould ◽  
...  
Keyword(s):  
Risk Factors ◽  
Phylogenetic Analysis ◽  
Human Population ◽  
Dairy Farms ◽  
Generation Cephalosporin ◽  
Third Generation ◽  
E Coli ◽  
Increased Risk ◽  
Amoxicillin Clavulanate ◽  
Cephalosporin Resistance

Abstract Objectives To characterize putative AmpC-hyperproducing third-generation cephalosporin-resistant E. coli from dairy farms and their phylogenetic relationships; to identify risk factors for their presence; and to assess evidence for their zoonotic transmission into the local human population. Methods Proteomics was used to explain differences in antimicrobial susceptibility. WGS allowed phylogenetic analysis. Multilevel, multivariable logistic regression modelling was used to identify risk factors. Results Increased use of amoxicillin/clavulanate was associated with an increased risk of finding AmpC hyperproducers on farms. Expansion of cephalosporin resistance in AmpC hyperproducers was seen in farm isolates with marR mutations (conferring cefoperazone resistance) or when AmpC was mutated (conferring fourth-generation cephalosporin and cefoperazone resistance). Phylogenetic analysis confirmed the dominance of ST88 amongst farm AmpC hyperproducers but there was no evidence for acquisition of farm isolates by members of the local human population. Conclusions Clear evidence was found for recent farm-to-farm transmission of AmpC-hyperproducing E. coli and of adaptive mutations to expand resistance. Whilst there was no evidence of isolates entering the local human population, efforts to reduce third-generation cephalosporin resistance on dairy farms must address the high prevalence of AmpC hyperproducers. The finding that amoxicillin/clavulanate use was associated with an increased risk of finding AmpC hyperproducers is important because this is not currently categorized as a highest-priority critically important antimicrobial and so is not currently targeted for specific usage restrictions in the UK.

scholarly journals Colonization with third-generation cephalosporin-resistant Enterobacteriaceae on hospital admission: prevalence and risk factors

2016 ◽  
Vol 71 (10) ◽  
pp. 2957-2963 ◽  
Author(s):  
A. Hamprecht ◽  
A. M. Rohde ◽  
M. Behnke ◽  
S. Feihl ◽  
P. Gastmeier ◽  
...  
Keyword(s):  
Risk Factors ◽  
Hospital Admission ◽  
Generation Cephalosporin ◽  
Third Generation ◽  
Admission Prevalence

scholarly journals Risk Factors for Emergence of Resistance to Broad-Spectrum Cephalosporins among Enterobacterspp

2001 ◽  
Vol 45 (9) ◽  
pp. 2628-2630 ◽  
Author(s):  
Keith S. Kaye ◽  
Sara Cosgrove ◽  
Anthony Harris ◽  
George M. Eliopoulos ◽  
Yehuda Carmeli
Keyword(s):  
Risk Factors ◽  
Relative Risk ◽  
Broad Spectrum ◽  
Generation Cephalosporin ◽  
Third Generation ◽  
Independent Risk Factors ◽  
Emergence Of Resistance

ABSTRACT Among 477 patients with susceptible Enterobacter spp., 49 subsequently harbored third-generation cephalosporin-resistantEnterobacter spp. Broad-spectrum cephalosporins were independent risk factors for resistance (relative risk [OR] = 2.3, P = 0.01); quinolone therapy was protective (OR = 0.4, P = 0.03). There were trends toward decreased risk for resistance among patients receiving broad-spectrum cephalosporins and either aminoglycosides or imipenem. Of the patients receiving broad-spectrum cephalosporins, 19% developed resistance.

Prevalence of third-generation cephalosporin-resistant Enterobacterales colonization on hospital admission and ESBL genotype-specific risk factors: a cross-sectional study in six German university hospitals

2020 ◽  
Vol 75 (6) ◽  
pp. 1631-1638
Author(s):  
Anna M Rohde ◽  
Janine Zweigner ◽  
Miriam Wiese-Posselt ◽  
Frank Schwab ◽  
Michael Behnke ◽  
...  
Keyword(s):  
Risk Factors ◽  
Risk Factor ◽  
Hospital Stay ◽  
Generation Cephalosporin ◽  
Resistant Bacteria ◽  
Third Generation ◽  
University Hospitals ◽  
Term Care ◽  
Specific Risk ◽  
M 14

Abstract Objectives To assess the admission prevalence of third-generation cephalosporin-resistant Enterobacterales (3GCREB) and to assess whether risk factors vary by β-lactamase genotype. Methods Adult patients were recruited within 72 h of admission to general wards of six university hospitals in 2014 and 2015. Rectal swabs were screened for 3GCREB and isolates were analysed phenotypically and genotypically. Patients were questioned on potential risk factors. Multivariable analyses were performed to identify risk factors for 3GCREB colonization and for specific β-lactamases. Results Of 8753 patients screened, 828 were 3GCREB positive (9.5%). Eight hundred and thirteen isolates were available for genotyping. CTX-M-15 was the most common ESBL (38.0%), followed by CTX-M-1 (22.5%), CTX-M-14 (8.7%), CTX-M-27 (7.5%) and SHV-ESBL (4.4%). AmpC was found in 11.9%. Interestingly, 18 Escherichia coli isolates were AmpC positive, 12 of which (67%) contained AmpC on a gene of plasmid origin [CMY (n = 10), DHA (n = 2)]. Risk factors for 3GCREB colonization varied by genotype. Recent antibiotic exposure and prior colonization by antibiotic-resistant bacteria were risk factors for all β-lactamases except CTX-M-14 and CTX-M-27. Travel outside Europe was a risk factor for CTX-M-15 and CTX-M-27 [adjusted OR (aOR) 3.49, 95% CI 2.88–4.24 and aOR 2.73, 95% CI 1.68–4.43]. A previous stay in a long-term care facility was associated with CTX-M-14 (aOR 3.01, 95% CI 1.98–4.59). A preceding hospital stay in Germany increased the risk of CTX-M-15 (aOR 1.27, 95% CI 1.14–1.41), while a prior hospital stay in other European countries increased the risk of SHV-ESBL colonization (aOR 3.85, 95% CI 1.67–8.92). Conclusions The detection of different ESBL types is associated with specific risk factor sets that might represent distinct sources of colonization and ESBL-specific dissemination routes.

Risk factors for the isolation of a third generation cephalosporin resistant strain in patients with community-acquired Enterobacteriaceae bacteraemia

2016 ◽  
Vol 72 (2) ◽  
pp. 268-271 ◽  
Author(s):  
M. Ortega ◽  
A. Soriano ◽  
F. Marco ◽  
M. Almela ◽  
J.A. Martínez ◽  
...  
Keyword(s):  
Risk Factors ◽  
Resistant Strain ◽  
Generation Cephalosporin ◽  
Third Generation

scholarly journals Clinical Benefit of Appropriate Empirical Fluoroquinolone Therapy for Adults with Community-Onset Bacteremia in Comparison with Third-Generation-Cephalosporin Therapy

2016 ◽  
Vol 61 (2) ◽  
Author(s):  
Ching-Chi Lee ◽  
Jiun-Ling Wang ◽  
Chung-Hsun Lee ◽  
Chih-Chia Hsieh ◽  
Yuan-Pin Hung ◽  
...  
Keyword(s):  
Critical Illness ◽  
Propensity Scores ◽  
Fatal Outcome ◽  
Group Versus ◽  
Bloodstream Infections ◽  
Generation Cephalosporin ◽  
Third Generation ◽  
Crude Mortality ◽  
Group A ◽  
Community Onset

ABSTRACT Both fluoroquinolones (FQs) and third-generation cephalosporins (3rd-GCs) are commonly prescribed to treat bloodstream infections, but comparative efficacies between them were rarely studied. Demographics and clinical characteristics of 733 adults with polymicrobial or monomicrobial community-onset bacteremia empirically treated by an appropriate FQ (n = 87) or 3rd-GC (n = 646) were compared. A critical illness (respectively, 8.0% versus 19.0%; P = 0.01), an initial syndrome with severe sepsis (33.3% versus 50.3%; P = 0.003), or a fatal outcome at 28 days (4.6% versus 10.5%; P = 0.08) was less common in the FQ group. A total of 645 (88.0%) patients were febrile at initial presentation, and the FQ group with (FQ group versus 3rd-GC group, respectively, 7.6 days versus 12.0 days; P = 0.04) and without (3.8 days versus 5.4 days; P = 0.001) a critical illness had a shorter time to defervescence than the 3rd-GC group. By the propensity scores, 87 patients with appropriate FQ therapy were matched with 435 treated by 3rd-GC therapy at a ratio of 1:5, and there were no significant differences in terms of bacteremia severity, comorbidity severity, major comorbidities, causative microorganisms, and bacteremia sources between groups. Moreover, crude mortality rates at 28 days (FQ group versus 3rd-GC group, respectively, 4.6% versus 7.8%; P = 0.29) did not differ significantly. However, the time to defervescence was shorter in the FQ group (4.2 ± 3.6 versus 6.2 ± 7.6 days; P < 0.001). Conclusively in the adults with community-onset bacteremia, appropriate empirical FQ therapy was related to shorter time to defervescence than with 3rd-GC therapy, at least for those without a critical illness.

scholarly journals Candidemia: Predisposing Factors, Antifungal Susceptibility, Clinical Outcome and Connotations for Management

2020 ◽  
Vol 41 (S1) ◽  
pp. s148-s148
Author(s):  
Abeera Ahmed ◽  
Nargis Daud ◽  
Lahore Gohar Zaman ◽  
Aamer Ikram ◽  
Muhammed Tahir Khadim
Keyword(s):  
Risk Factors ◽  
Mortality Rate ◽  
Prospective Observational Study ◽  
Antifungal Agents ◽  
Antifungal Susceptibility ◽  
Crude Mortality ◽  
Failure Assessment ◽  
Break Points ◽  
Initiation Of Therapy

Objective: We conducted this study to investigate the epidemiology of candidemia in our setting and to quantify the risk factors associated with disease, overall outcome, and mortality associated with candidemia. Methods: In this prospective observational study, we conducted lab-based surveillance with clinical correlation of all cases of candidemia within our ICUs during the period (2016–2018). Clinical assessment was done on day 5 and day 30, and comorbidities, clinical features, and outcome were observed within 30 days after the diagnosis. The diagnosis was made on the basis of positive blood culture for Candida spp and a compatible clinical picture. The demographic characteristics, sequential organ failure assessment (SOFA) scores, comorbidities, use of invasive devices, antibiotics administered were observed, and antifungal susceptibility testing was performed according to CLSI guidelines. Type and duration of antifungal administered and outcomes were noted. Results: In total, 48 episodes of candidemia, with 29 (60%) males and 19 (40%) females, were identified during the study period. C. albicans was the most common specie responsible for candidemia, causing 17 of the cases (~35%), whereas rest of the cases were caused by non–albicans spp, which included C. auris, accounting for 9 (19%) C. parapsilosis and C. tropicalis 7 (15%) each, C. glabrata and C. famata 2 (6%), and C. krusei was isolated in only 2 cases (4%). Among modifiable risk factors, CVC insertion and antibiotic exposure were the leading factors, seen in 100% of patient. Candida colonization was observed in 26 patients (28%), of whom 2 (4%) had multifocal Candida colonization. Among evaluable patients, 17 (35%) died within 30 days of the onset of candidemia. C. tropicalis was associated with the highest mortality rate, 27% (n = 4) in this cohort. Regarding the crude mortality in the different units, patients in medical ICU had the highest mortality rate (54%). In vitro activity of 3 systemically active antifungal agents was tested against 48 isolates of Candida spp. Based on CLSI break points, the susceptibility to voriconazole was 98%; only 1 isolate was resistant to voriconazole. Among candidemia-positive cases, 28 patients (58%) had taken the antifungals for >14 days, whereas 18 (37.5%) were treated for <14 days and 2 (4%) died before the initiation of therapy. Conclusions: In our study, C. albicans was the most common specie responsible for candidemia, but non–albicans spp are also emerging, with higher in vitro resistance to antifungals.Funding: NoneDisclosures: None

Sign in / Sign up

Export Citation Format

Share Document